Preclinical study demonstrates strong anti-proliferative activity and GPC-3 binding in hepatic cancer cells, suggesting potential as hepatocellular carcinoma therapeutics.
All the tested compounds had exhibited good anti-proliferative efficacy against hepatic cancer cell lines. In addition, the molecular docking results showed strong binding interactions of the synthesized compounds with the target GPC-3 protein with lower energy scores. Thus, such novel compounds may act as promising candidates as drugs against hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Rashdan et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: